Healthcare · Drug Manufacturers Specialty Generic · NASDAQ
HUTCHMED (China) (HCM) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $2.64B and a free-cash-flow yield of -3.4%. Over the most recent reported fiscal year, revenue declined 13.0%. Nama's AI scorecard rates it Sell, 3.2 out of 10. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Sell · 3.2/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Momentum
Lagging · -7.6% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-58.3%
How far the last close sits under the highest price of the past five years.
Market cap
$2.64B
Trailing P/E
—
Price / book
10.5
Price / sales
4.8
FCF yield
-3.4%
Dividend yield
—
Gross margin
13.3%
Operating margin
0.3%
Net margin
3.3%
Revenue growth (YoY)
-13.0%
Revenue growth (3-yr annual)
+8.8%
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.4
Exchange
NASDAQ
Sector
Healthcare
Industry
Drug Manufacturers Specialty Generic
HCM earnings
Beat the EPS estimate in 3 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q4 2021
Mar 2, 2022
-$0.03
-$0.13
+76.9%
—
Q2 2021
Jul 28, 2021
-$0.40
-$0.07
-471.4%
—
Q1 2021
Jun 21, 2021
-$0.30
-$0.37
+18.9%
—
Q4 2020
Mar 4, 2021
-$0.03
-$0.13
+76.9%
—
HCM analyst price target
Median target $19.50 from 12 analysts, ranging $13.60 – $33.27.
Nama's AI scorecard currently rates HUTCHMED (China) Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is the HCM price target?
The median analyst price target from 12 analysts is $19.50, with a range of $13.60 – $33.27.
Is HCM Shariah compliant?
Nama's AAOIFI-style screen reads HUTCHMED (China) as Not Shariah Compliant. At least one of the three ratios or the industry test failed.